Plain-English answer
DIP payment reform, or Diagnosis-Intervention Packet payment, is China's big-data-based inpatient payment method that groups cases by diagnosis and intervention combinations and pays within a regional point and budget system. It is often discussed together with DRG reform but uses a different grouping and settlement logic.
Policy context
NHSA advanced DRG and DIP reform together after national pilots. The three-year action plan named both methods and connected them to a more efficient medical-insurance payment mechanism. DIP is especially associated with using large volumes of claims data to assign point values to case combinations, then settling hospitals within a regional insurance budget.
Operating model
DIP changes hospital incentives by turning each admission into a point-valued case rather than an open-ended bill. Hospitals must manage total resource use, avoid unnecessary services, and pay attention to coding accuracy. The method can reward efficiency but can also create risks of upcoding, avoidance of complex patients, or pressure to reduce services if quality monitoring is weak.
Strategic reading
For companies, DIP makes hospital economics more local and data-driven. A product may be attractive in one city if it improves outcomes inside a DIP group but unattractive elsewhere if the point value does not cover cost. Market access therefore requires understanding local DIP rules, case-group economics, and how the product affects hospital settlement under real claims data.
Decision test
For DIP Payment Reform in China, the practical test is whether the analysis identifies the payer rule, hospital incentive, procurement route, affected product category, and implementation level. A page that only says China wants lower prices is not useful. The specific question is who changes behavior, under which rule, with what price, budget, quality, and access consequence.
Implementation detail
DIP Payment Reform in China should be read through the full chain of Chinese healthcare finance: policy design, provincial or national implementation, hospital operating response, department-level behavior, and patient access. A reform can lower headline prices while still creating new questions about quality, supply, service availability, hospital incentives, and whether the savings reach patients in the form of usable care. The relevant evidence is therefore not only the announced policy, but also how hospitals, manufacturers, physicians, distributors, and insurers respond after implementation.
For market access, the page is most useful when it separates four layers. The first is the formal rule: who issued it, which products or services it covers, and when it applies. The second is the payment consequence: who loses margin, gains volume, absorbs cost, or changes budget risk. The third is the clinical consequence: whether physicians and hospitals can still choose the product, service, or workflow that fits the patient. The fourth is the commercialization consequence: whether a company should compete, differentiate, localize, redesign the channel, gather new evidence, or avoid the category. Without those layers, payment and procurement reform sounds abstract even though it directly determines adoption.